AbbVie (ABBV) announced that the FDA has granted approval to its blockbuster drug, Skyrizi to treat adults with moderately to severely active ulcerative colitis (UC) in the United States. Skyrizi’s approval for the UC indication was based on data from two phase III studies, a 12-week induction study, INSPIRE1 and a 52-week maintenance study, COMMAND2. Both studies achieved the primary endpoint of clinical remission. The studies also achieved a key secondary endpoint of endoscopic improvement. Skyrizi is alr ...